{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:42:26Z","timestamp":1790516546012,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics, Inc","doi-asserted-by":"crossref","award":["HEALTH-F4-2012-30537"],"award-info":[{"award-number":["HEALTH-F4-2012-30537"]}],"id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","award":["Cl 15121 A20256"],"award-info":[{"award-number":["Cl 15121 A20256"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>During the last decade, multiple clinical trials for Duchenne muscular dystrophy (DMD) have focused on the induction of dystrophin expression using different strategies. Many of these trials have reported a clear increase in dystrophin protein following treatment. However, the low levels of the induced dystrophin protein have raised questions on its functionality. In our present study, using an unbiased, high-throughput digital image analysis platform, we assessed markers of regeneration and levels of dystrophin associated protein via immunofluorescent analysis of whole muscle sections in 25 DMD boys who received 48-weeks treatment with exon 53 skipping morpholino antisense oligonucleotide (PMO) golodirsen. We demonstrate that the de novo dystrophin induced by exon skipping with PMO golodirsen is capable of conferring a histological benefit in treated patients with an increase in dystrophin associated proteins at the dystrophin positive regions of the sarcolemma in post-treatment biopsies. Although 48\u00a0weeks treatment with golodirsen did not result in a significant change in the levels of fetal\/developmental myosins for the entire cohort, there was a significant negative correlation between the amount of dystrophin and levels of regeneration observed in different biopsy samples. Our results provide, for the first time, evidence of functionality of induced dystrophin following successful therapeutic intervention in the human.<\/jats:p>","DOI":"10.1186\/s40478-020-01106-1","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T22:03:49Z","timestamp":1609970629000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0441-2198","authenticated-orcid":false,"given":"Dominic","family":"Scaglioni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Torelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Sewry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Monforte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Harriman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Popplewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Guglieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Straub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Servais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Phadke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Muntoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"key":"1106_CR1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/humu.20918","volume":"30","author":"A Aartsma-Rus","year":"2009","unstructured":"Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom J, van Ommen G-J, den Dunnen JT (2009) Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 30:293\u2013299. https:\/\/doi.org\/10.1002\/humu.20918","journal-title":"Hum Mutat"},{"key":"1106_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1089\/nat.2017.0682","volume":"27","author":"A Aartsma-Rus","year":"2017","unstructured":"Aartsma-Rus A, Straub V, Hemmings R, Haas M, Schlosser-Weber G, Stoyanova-Beninska V, Mercuri E, Muntoni F, Sepodes B, Vroom E, Balabanov P (2017) Development of exon skipping therapies for duchenne muscular dystrophy: a critical review and a perspective on the outstanding issues. Nucleic Acid Ther 27:251\u2013259. https:\/\/doi.org\/10.1089\/nat.2017.0682","journal-title":"Nucleic Acid Ther"},{"key":"1106_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1001\/jamaneurol.2013.4908","volume":"71","author":"K Anthony","year":"2014","unstructured":"Anthony K, Arechavala-Gomeza V, Ricotti V, Torelli S, Feng L, Janghra N, Tasca G, Guglieri M, Barresi R, Armaroli A, Ferlini A, Bushby K, Straub V, Ricci E, Sewry C, Morgan J, Muntoni F (2014) Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping. JAMA Neurol 71:32\u201340. https:\/\/doi.org\/10.1001\/jamaneurol.2013.4908","journal-title":"JAMA Neurol"},{"key":"1106_CR4","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1093\/brain\/awr291","volume":"134","author":"K Anthony","year":"2011","unstructured":"Anthony K, Cirak S, Torelli S, Tasca G, Feng L, Arechavala-Gomeza V, Armaroli A, Guglieri M, Straathof CS, Verschuuren JJ, Aartsma-Rus A, Helderman-van den Enden P, Bushby K, Straub V, Sewry C, Ferlini A, Ricci E, Morgan JE, Muntoni F (2011) Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. Brain 134:3547\u20133559. https:\/\/doi.org\/10.1093\/brain\/awr291","journal-title":"Brain"},{"key":"1106_CR5","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1212\/wnl.0000000000002891","volume":"87","author":"L Bello","year":"2016","unstructured":"Bello L, Morgenroth LP, Gordish-Dressman H, Hoffman EP, McDonald CM, Cirak S (2016) DMD genotypes and loss of ambulation in the CINRG Duchenne natural history study. Neurology 87:401\u2013409. https:\/\/doi.org\/10.1212\/wnl.0000000000002891","journal-title":"Neurology"},{"key":"1106_CR6","doi-asserted-by":"publisher","first-page":"e0218683","DOI":"10.1371\/journal.pone.0218683","volume":"14","author":"C Brogna","year":"2019","unstructured":"Brogna C, Coratti G, Pane M, Ricotti V, Messina S, D\u2019Amico A, Bruno C, Vita G, Berardinelli A, Mazzone E, Magri F, Ricci F, Mongini T, Battini R, Bello L, Pegoraro E, Baranello G, Previtali SC, Politano L, Comi GP, Sansone VA, Donati A, Bertini E, Muntoni F, Goemans N, Mercuri E, on behalf on the International DMD group (2019) Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53. PLoS ONE 14:e0218683. https:\/\/doi.org\/10.1371\/journal.pone.0218683","journal-title":"PLoS ONE"},{"key":"1106_CR7","doi-asserted-by":"publisher","first-page":"e2146","DOI":"10.1212\/wnl.0000000000005680","volume":"90","author":"JS Charleston","year":"2018","unstructured":"Charleston JS, Schnell FJ, Dworzak J, Donoghue C, Lewis S, Chen L, Young GD, Milici AJ, Voss J, DeAlwis U, Wentworth B, Rodino-Klapac LR, Sahenk Z, Frank D, Mendell JR (2018) Eteplirsen treatment for Duchenne muscular dystrophy: exon skipping and dystrophin production. Neurology 90:e2146\u2013e2154. https:\/\/doi.org\/10.1212\/wnl.0000000000005680","journal-title":"Neurology"},{"key":"1106_CR8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/s0140-6736(11)60756-3","volume":"378","author":"S Cirak","year":"2011","unstructured":"Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, Anthony K, Abbs S, Garralda ME, Bourke J, Wells DJ, Dickson G, Wood MJA, Wilton SD, Straub V, Kole R, Shrewsbury SB, Sewry C, Morgan JE, Bushby K, Muntoni F (2011) Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378:595\u2013605. https:\/\/doi.org\/10.1016\/s0140-6736(11)60756-3","journal-title":"Lancet"},{"key":"1106_CR9","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/mt.2011.248","volume":"20","author":"S Cirak","year":"2012","unstructured":"Cirak S, Feng L, Anthony K, Arechavala-Gomeza V, Torelli S, Sewry C, Morgan JE, Muntoni F (2012) Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in duchenne muscular dystrophy. Mol Ther 20:462\u2013467. https:\/\/doi.org\/10.1038\/mt.2011.248","journal-title":"Mol Ther"},{"key":"1106_CR10","doi-asserted-by":"publisher","first-page":"C651","DOI":"10.1152\/ajpcell.00244.2007","volume":"294","author":"DR Claflin","year":"2008","unstructured":"Claflin DR, Brooks SV (2008) Direct observation of failing fibers in muscles of dystrophic mice provides mechanistic insight into muscular dystrophy. Am J Physiol Cell Physiol 294:C651\u2013658. https:\/\/doi.org\/10.1152\/ajpcell.00244.2007","journal-title":"Am J Physiol Cell Physiol"},{"key":"1106_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1264","author":"PR Clemens","year":"2020","unstructured":"Clemens PR, Rao VK, Connolly AM, Harper AD, Mah JK, Smith EC, McDonald CM, Zaidman CM, Morgenroth LP, Osaki H, Satou Y, Yamashita T, Hoffman EP, Investigators CINRGDNHS (2020) Safety, tolerability, and efficacy of viltolarsen in boys with duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1264","journal-title":"JAMA Neurol"},{"key":"1106_CR12","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.bbamem.2013.08.023","volume":"1838","author":"B Constantin","year":"2014","unstructured":"Constantin B (2014) Dystrophin complex functions as a scaffold for signalling proteins. Biochimica et Biophysica Acta (BBA) Biomembranes 1838:635\u2013642. https:\/\/doi.org\/10.1016\/j.bbamem.2013.08.023","journal-title":"Biochimica et Biophysica Acta (BBA) Biomembranes"},{"key":"1106_CR13","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","volume":"26","author":"D Duan","year":"2018","unstructured":"Duan D (2018) Systemic AAV micro-dystrophin gene therapy for duchenne muscular dystrophy. Mol Ther 26:2337\u20132356. https:\/\/doi.org\/10.1016\/j.ymthe.2018.07.011","journal-title":"Mol Ther"},{"key":"1106_CR14","unstructured":"Dubowitz V, Oldfors A, Sewry CA (2020) Muscle biopsy: a practical approach"},{"key":"1106_CR15","doi-asserted-by":"publisher","first-page":"13591","DOI":"10.1074\/jbc.r200021200","volume":"278","author":"JM Ervasti","year":"2003","unstructured":"Ervasti JM (2003) Costameres: the Achilles\u2019 Heel of Herculean muscle. J Biol Chem 278:13591\u201313594. https:\/\/doi.org\/10.1074\/jbc.r200021200","journal-title":"J Biol Chem"},{"key":"1106_CR16","volume-title":"Structure and function of the dystrophin-glycoprotein complex","author":"JM Ervasti","year":"2013","unstructured":"Ervasti JM (2013) Structure and function of the dystrophin-glycoprotein complex. Landes Bioscience, Austin"},{"key":"1106_CR17","doi-asserted-by":"publisher","first-page":"e81302","DOI":"10.1371\/journal.pone.0081302","volume":"8","author":"RS Finkel","year":"2013","unstructured":"Finkel RS, Flanigan KM, Wong B, B\u00f6nnemann C, Sampson J, Sweeney HL, Reha A, Northcutt VJ, Elfring G, Barth J, Peltz SW (2013) Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy. PLoS ONE 8:e81302. https:\/\/doi.org\/10.1371\/journal.pone.0081302","journal-title":"PLoS ONE"},{"key":"1106_CR18","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ncl.2014.05.002","volume":"32","author":"KM Flanigan","year":"2014","unstructured":"Flanigan KM (2014) Duchenne and Becker muscular dystrophies. Neurol Clin 32:671\u2013688. https:\/\/doi.org\/10.1016\/j.ncl.2014.05.002","journal-title":"Neurol Clin"},{"key":"1106_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1212\/wnl.0000000000009233","volume":"10","author":"DE Frank","year":"2020","unstructured":"Frank DE, Schnell FJ, Akana C, El-Husayni SH, Desjardins CA, Morgan J, Charleston JS, Sardone V, Domingos J, Dickson G, Straub V, Guglieri M, Mercuri E, Servais L, Muntoni F (2020) Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. Neurology 10:15\u201320. https:\/\/doi.org\/10.1212\/wnl.0000000000009233","journal-title":"Neurology"},{"key":"1106_CR20","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/cphy.c140048","volume":"5","author":"QQ Gao","year":"2015","unstructured":"Gao QQ, McNally EM (2015) The dystrophin complex: structure, function, and implications for therapy. Compr Physiol 5:1223\u20131239. https:\/\/doi.org\/10.1002\/cphy.c140048","journal-title":"Compr Physiol"},{"key":"1106_CR21","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.4103\/1673-5374.253534","volume":"14","author":"S Guiraud","year":"2019","unstructured":"Guiraud S, Davies KE (2019) Regenerative biomarkers for Duchenne muscular dystrophy. Neural Regener Res 14:1317. https:\/\/doi.org\/10.4103\/1673-5374.253534","journal-title":"Neural Regener Res"},{"key":"1106_CR22","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/hmg\/ddy353","volume":"28","author":"S Guiraud","year":"2019","unstructured":"Guiraud S, Edwards B, Squire SE, Moir L, Berg A, Babbs A, Ramadan N, Wood MJ, Davies KE (2019) Embryonic myosin is a regeneration marker to monitor utrophin-based therapies for DMD. Hum Mol Genet 28:307\u2013319. https:\/\/doi.org\/10.1093\/hmg\/ddy353","journal-title":"Hum Mol Genet"},{"key":"1106_CR23","doi-asserted-by":"publisher","first-page":"210797","DOI":"10.1155\/2011\/210797","volume":"2011","author":"JD Gumerson","year":"2011","unstructured":"Gumerson JD, Michele DE (2011) The dystrophin-glycoprotein complex in the prevention of muscle damage. J Biomed Biotechnol 2011:210797. https:\/\/doi.org\/10.1155\/2011\/210797","journal-title":"J Biomed Biotechnol"},{"key":"1106_CR24","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman EP, Brown RH, Kunkel LM (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51:919\u2013928. https:\/\/doi.org\/10.1016\/0092-8674(87)90579-4","journal-title":"Cell"},{"key":"1106_CR25","doi-asserted-by":"publisher","first-page":"e0150818","DOI":"10.1371\/journal.pone.0150818","volume":"11","author":"N Janghra","year":"2016","unstructured":"Janghra N, Morgan JE, Sewry CA, Wilson FX, Davies KE, Muntoni F, Tinsley J (2016) Correlation of utrophin levels with the dystrophin protein complex and muscle fibre regeneration in duchenne and becker muscular dystrophy muscle biopsies. PLoS ONE 11:e0150818. https:\/\/doi.org\/10.1371\/journal.pone.0150818","journal-title":"PLoS ONE"},{"key":"1106_CR26","first-page":"498","volume":"45","author":"M Koenig","year":"1989","unstructured":"Koenig M, Beggs AH, Moyer M, Scherpf S, Heindrich K, Bettecken T, Meng G, M\u00fcller CR, Lindl\u00f6f M, Kaariainen H, de la Chapelle A, Kiuru A, Savontaus M-L, Gilgenkrantz H, R\u00e9can D, Chelly J, Kaplan J-C, Covone AE, Archidiacono N, Romeo G, Liechti-Gallati S, Schneider V, Braga S, Moser H, Darras BT, Murphy P, Francke U, Chen JD, Morgan G, Denton M, Greenberg CR, Wrogemann K, Blonden LAJ, van Paassen HMB, van Ommen GJB, Kunkel LM (1989) The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 45:498\u2013506","journal-title":"Am J Hum Genet"},{"key":"1106_CR27","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.2353\/ajpath.2008.071042","volume":"172","author":"D Li","year":"2008","unstructured":"Li D, Yue Y, Duan D (2008) Preservation of muscle force in Mdx3cv mice correlates with low-level expression of a near full-length dystrophin protein. Am J Pathol 172:1332\u20131341. https:\/\/doi.org\/10.2353\/ajpath.2008.071042","journal-title":"Am J Pathol"},{"key":"1106_CR28","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/mt.2010.261","volume":"19","author":"A Malerba","year":"2011","unstructured":"Malerba A, Sharp PS, Graham IR, Arechavala-Gomeza V, Foster K, Muntoni F, Wells DJ, Dickson G (2011) Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice. Mol Ther 19:345\u2013354. https:\/\/doi.org\/10.1038\/mt.2010.261","journal-title":"Mol Ther"},{"key":"1106_CR29","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/ana.23982","volume":"74","author":"JR Mendell","year":"2013","unstructured":"Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, Alfano L, Gomez AM, Lewis S, Kota J, Malik V, Shontz K, Walker CM, Flanigan KM, Corridore M, Kean JR, Allen HD, Shilling C, Melia KR, Sazani P, Saoud JB, Kaye EM, Eteplirsen Study Group (2013) Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 74:637\u2013647. https:\/\/doi.org\/10.1002\/ana.23982","journal-title":"Ann Neurol"},{"key":"1106_CR30","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/ana.23528","volume":"71","author":"JR Mendell","year":"2012","unstructured":"Mendell JR, Shilling C, Leslie ND, Flanigan KM, Al-Dahhak R, Gastier-Foster J, Kneile K, Dunn DM, Duval B, Aoyagi A, Hamil C, Mahmoud M, Roush K, Bird L, Rankin C, Lilly H, Street N, Chandrasekar R, Weiss RB (2012) Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol 71:304\u2013313. https:\/\/doi.org\/10.1002\/ana.23528","journal-title":"Ann Neurol"},{"key":"1106_CR31","doi-asserted-by":"publisher","first-page":"19750","DOI":"10.1038\/srep19750","volume":"6","author":"J Meng","year":"2016","unstructured":"Meng J, Counsell JR, Reza M, Laval SH, Danos O, Thrasher A, Lochm\u00fcller H, Muntoni F, Morgan JE (2016) Autologous skeletal muscle derived cells expressing a novel functional dystrophin provide a potential therapy for Duchenne muscular dystrophy. Sci Rep 6:19750. https:\/\/doi.org\/10.1038\/srep19750","journal-title":"Sci Rep"},{"key":"1106_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.scr.2018.05.004","volume":"30","author":"J Meng","year":"2018","unstructured":"Meng J, Muntoni F, Morgan J (2018) CD133\u2009+\u2009cells derived from skeletal muscles of Duchenne muscular dystrophy patients have a compromised myogenic and muscle regenerative capability. Stem Cell Res 30:43\u201352. https:\/\/doi.org\/10.1016\/j.scr.2018.05.004","journal-title":"Stem Cell Res"},{"key":"1106_CR33","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.nmd.2007.07.005","volume":"17","author":"M Neri","year":"2007","unstructured":"Neri M, Torelli S, Brown S, Ugo I, Sabatelli P, Merlini L, Spitali P, Rimessi P, Gualandi F, Sewry C, Ferlini A, Muntoni F (2007) Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human. Neuromuscul Disord 17:913\u2013918. https:\/\/doi.org\/10.1016\/j.nmd.2007.07.005","journal-title":"Neuromuscul Disord"},{"key":"1106_CR34","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.omtn.2017.10.014","volume":"9","author":"S Omairi","year":"2017","unstructured":"Omairi S, Hau K-L, Collin-Hooper H, Montanaro F, Goyenvalle A, Garcia L, Patel K (2017) Link between MHC fiber type and restoration of dystrophin expression and key components of the DAPC by tricyclo-DNA-mediated exon skipping. Mol Ther Nucleic Acids 9:409\u2013418. https:\/\/doi.org\/10.1016\/j.omtn.2017.10.014","journal-title":"Mol Ther Nucleic Acids"},{"key":"1106_CR35","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1016\/j.jaci.2015.12.1344","volume":"137","author":"DP Potaczek","year":"2016","unstructured":"Potaczek DP, Garn H, Unger SD, Renz H (2016) Antisense molecules: a\u00a0new class of drugs. J Allergy Clin Immunol 137:1334\u20131346. https:\/\/doi.org\/10.1016\/j.jaci.2015.12.1344","journal-title":"J Allergy Clin Immunol"},{"key":"1106_CR36","doi-asserted-by":"publisher","first-page":"e31937","DOI":"10.1371\/journal.pone.0031937","volume":"7","author":"M van Putten","year":"2012","unstructured":"van Putten M, Hulsker M, Nadarajah VD, van Heiningen SH, van Huizen E, van Iterson M, Admiraal P, Messemaker T, den Dunnen JT, \u2019t Hoen PAC, Aartsma-Rus A (2012) The effects of low levels of dystrophin on mouse muscle function and pathology. PLoS ONE 7:e31937. https:\/\/doi.org\/10.1371\/journal.pone.0031937","journal-title":"PLoS ONE"},{"key":"1106_CR37","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1096\/fj.12-224170","volume":"27","author":"M van Putten","year":"2013","unstructured":"van Putten M, Hulsker M, Young C, Nadarajah VD, Heemskerk H, van der Weerd L, \u2019t Hoen PAC, van Ommen GJB, Aartsma-Rus AM (2013) Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin\/utrophin double-knockout mice. FASEB J 27:2484\u20132495. https:\/\/doi.org\/10.1096\/fj.12-224170","journal-title":"FASEB J"},{"key":"1106_CR38","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1136\/jnnp-2014-309405","volume":"87","author":"V Ricotti","year":"2016","unstructured":"Ricotti V, Ridout DA, Pane M, Main M, Mayhew A, Mercuri E, Manzur AY, Muntoni F, UK NorthStar Clinical Network (2016) The NorthStar ambulatory assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials. J Neurol Neurosurg Psychiatry 87:149\u2013155. https:\/\/doi.org\/10.1136\/jnnp-2014-309405","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1106_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22040563","author":"V Sardone","year":"2017","unstructured":"Sardone V, Zhou H, Muntoni F, Ferlini A, Falzarano MS (2017) Antisense oligonucleotide-based therapy for neuromuscular disease. Molecules. https:\/\/doi.org\/10.3390\/molecules22040563","journal-title":"Molecules"},{"key":"1106_CR40","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40478-020-00918-5","volume":"8","author":"D Scaglioni","year":"2020","unstructured":"Scaglioni D, Ellis M, Catapano F, Torelli S, Chambers D, Feng L, Sewry C, Morgan J, Muntoni F, Phadke R (2020) A high\u2013throughput digital script for multiplexed immunofluorescent analysis and quantification of sarcolemmal and sarcomeric proteins in muscular dystrophies. Acta Neuropathol Commun 8:53. https:\/\/doi.org\/10.1186\/s40478-020-00918-5","journal-title":"Acta Neuropathol Commun"},{"key":"1106_CR41","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13395-015-0046-6","volume":"5","author":"S Schiaffino","year":"2015","unstructured":"Schiaffino S, Rossi AC, Smerdu V, Leinwand LA, Reggiani C (2015) Developmental myosins: expression patterns and functional significance. Skelet Muscle 5:22. https:\/\/doi.org\/10.1186\/s13395-015-0046-6","journal-title":"Skelet Muscle"},{"key":"1106_CR42","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/mt.2010.213","volume":"19","author":"PS Sharp","year":"2011","unstructured":"Sharp PS, Bye-a-Jee H, Wells DJ (2011) Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy. Mol Ther 19:165\u2013171. https:\/\/doi.org\/10.1038\/mt.2010.213","journal-title":"Mol Ther"},{"key":"1106_CR43","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13023-018-0834-2","volume":"13","author":"Y Shimizu-Motohashi","year":"2018","unstructured":"Shimizu-Motohashi Y, Murakami T, Kimura E, Komaki H, Watanabe N (2018) Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis. Orphanet J Rare Dis 13:93. https:\/\/doi.org\/10.1186\/s13023-018-0834-2","journal-title":"Orphanet J Rare Dis"},{"key":"1106_CR44","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1016\/j.nmd.2018.06.160","volume":"28","author":"J Tinsley","year":"2018","unstructured":"Tinsley J, Muntoni F, Layton G, Faelan C, Patterson-Kane J, Hetherington A, Davies K (2018) DMD clinical therapies II: P.132 identification of developmental myosin positive fibres acts both as a clinical biomarker for muscle disease and an important component of the process to confirm ezutromid target engagement. Neuromuscul Disord 28:S69. https:\/\/doi.org\/10.1016\/j.nmd.2018.06.160","journal-title":"Neuromuscul Disord"},{"key":"1106_CR45","doi-asserted-by":"publisher","first-page":"13714","DOI":"10.1073\/pnas.240335297","volume":"97","author":"B Wang","year":"2000","unstructured":"Wang B, Li J, Xiao X (2000) Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. PNAS 97:13714\u201313719. https:\/\/doi.org\/10.1073\/pnas.240335297","journal-title":"PNAS"},{"key":"1106_CR46","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.omtn.2018.09.017","volume":"13","author":"N Watanabe","year":"2018","unstructured":"Watanabe N, Nagata T, Satou Y, Masuda S, Saito T, Kitagawa H, Komaki H, Takagaki K, Takeda S (2018) NS-065\/NCNP-01: an antisense oligonucleotide for potential treatment of exon 53 skipping in Duchenne muscular dystrophy. Mol Ther Nucleic Acids 13:442\u2013449. https:\/\/doi.org\/10.1016\/j.omtn.2018.09.017","journal-title":"Mol Ther Nucleic Acids"},{"key":"1106_CR47","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/jcsm.12506","volume":"11","author":"TLE van Westering","year":"2020","unstructured":"van Westering TLE, Lomonosova Y, Coenen-Stass AML, Betts CA, Bhomra A, Hulsker M, Clark LE, McClorey G, Aartsma-Rus A, van Putten M, Wood MJA, Roberts TC (2020) Uniform sarcolemmal dystrophin expression is required to prevent extracellular microRNA release and improve dystrophic pathology. J Cachexia Sarcopenia Muscle 11:578\u2013593. https:\/\/doi.org\/10.1002\/jcsm.12506","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1106_CR48","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/jpc.12868","volume":"51","author":"EM Yiu","year":"2015","unstructured":"Yiu EM, Kornberg AJ (2015) Duchenne muscular dystrophy. J Paediatr Child Health 51:759\u2013764. https:\/\/doi.org\/10.1111\/jpc.12868","journal-title":"J Paediatr Child Health"},{"key":"1106_CR49","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.ymthe.2004.07.025","volume":"10","author":"M Yoshimura","year":"2004","unstructured":"Yoshimura M, Sakamoto M, Ikemoto M, Mochizuki Y, Yuasa K, Miyagoe-Suzuki Y, Takeda S (2004) AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype. Mol Ther 10:821\u2013828. https:\/\/doi.org\/10.1016\/j.ymthe.2004.07.025","journal-title":"Mol Ther"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-020-01106-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40478-020-01106-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-020-01106-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T23:40:22Z","timestamp":1609976422000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-020-01106-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,6]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1106"],"URL":"https:\/\/doi.org\/10.1186\/s40478-020-01106-1","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,6]]},"assertion":[{"value":"11 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FM has received consulting fees from Biogen, Italfarmaco, Pfizer, PTC Therapeutics, Roche, Sarepta Therapeutics, and Wave Therapeutics; and is supported by the National Institute of Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust, and University College London. LS received consulting fees from Sarepta, Roche, Pfizer, Novartis, Cytokynetics, Biogen, Regenexbio, Santhera, Affinia, Dynacure and Audentes. The views expressed in this paper are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki. Ethical approval was obtained in each of the participating centres (Newcastle and London, UK; Paris, France; and Rome, Italy)","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Parents or legal guardians of all patients provided written informed consent before study participation and genetic testing with all patients providing written assent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for participation and publication"}}],"article-number":"7"}}